1 domain / 2 areas / 1 specialization
PharmaDrugCSE: PHRX | OTC Pink: LMLLF
Data updated
PharmaDrug is a Canadian specialty pharmaceutical company focused on the research and development of controlled substances and natural medicines. Through its Sairiyo Therapeutics subsidiary, the company is developing a DMT candidate with FDA Orphan Drug Designation for prevention of ischemia-reperfusion injury in organ transplants, and is also studying DMT for ophthalmic indications. PharmaDrug also distributes medical cannabis in the EU via PharmaDrug Production GmbH.
Pipeline Intelligence
Developer Momentum
- Active candidates
- 1
- Active programmes
- 1
- Lead stage
- Preclinical
- Forecast coverage
- 1 of 1
All tracked candidates active
All tracked programmes active
Current furthest stage
1 active programme with forecast fields
Latest sourced update
Jul 30, 2025 - Press release - StockTitan - DMT (Ischemia-Reperfusion / Organ Transplant) / DMT Orphan Drug Programme (Ischemia-Reperfusion) — STALLED
Next known catalyst
No next milestone forecast yet.
Development Programmes
1DMT (Ischemia-Reperfusion / Organ Transplant)
DMTIschemia-reperfusion injury / organ transplantation
Programme Tracker
Neurological Injury
Programme appears stalled since 2021 ODD grant; no clinical advancement reported; company pivoting to cepharanthine
Milestones
regulatory-designation
CompletedActual: Apr 1, 2021
FDA grants first-ever Orphan Drug Designation for DMT (ischemia-reperfusion injury in organ transplantation)
Why it matters: Historic regulatory milestone — first ODD for any psychedelic compound. Targets DMT's sigma-1 receptor activity (not 5-HT2A psychedelic effect) to protect organs from ischemia-reperfusion damage. ODD provides 7-year market exclusivity and reduced filing fees.
Company milestone
CompletedActual: Feb 1, 2023
Research collaboration with PharmaTher for DMT microneedle transdermal patch development
Why it matters: Transdermal delivery could enable controlled, sub-psychedelic DMT dosing for cytoprotective applications.
Company milestone
CompletedActual: Jun 1, 2025
Board forms special committee for comprehensive strategic review; company pivoting toward cepharanthine (PD-001) and Canurta Biotech botanical drugs
Why it matters: Strategic review signals DMT programme has been deprioritized. PharmaDrug appears to be pivoting its clinical resources toward PD-001 (cepharanthine for viral diseases) via Sairiyo Therapeutics subsidiary and botanical neurodegeneration drugs via Canurta.
Recorded Events
Jun 1, 2025: Company milestone
Feb 1, 2023: Company milestone
Apr 1, 2021: regulatory-designation
Quick Facts
- Type
- Public Biotech
- Ticker
- CSE: PHRX | OTC Pink: LMLLF
- Lead Stage
- Preclinical
- Website
- Visit